FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890779740> ?p ?o ?g. }

• W2890779740 endingPage "8012" @default.
• W2890779740 startingPage "8012" @default.
• W2890779740 abstract "8012 Background: Elotuzumab is an approved monoclonal antibody targeting SLAMF7 on NK cells and plasma cells that enhances the activity of lenalidomide and bortezomib in multiple myeloma (MM). We studied elotuzumab with pomalidomide, bortezomib, and dexamethasone (elo-PVD) in relapsed and refractory MM. Methods: The primary objective was to determine the overall response rate (ORR). Patients with refractory disease and ≥1 prior lines of treatment (including lenalidomide and a proteasome inhibitor) were eligible to participate. Elotuzumab was weekly for the first 2 cycles and then every other week. Pomalidomide was on days 1-21; bortezomib was on days 1, 8, 15; and dexamethasone was weekly. Each cycle was 28 days. Results: At time of data cutoff, 33 patients (pts) who started treatment were evaluable. The median age was 64 (range 52-79), and the median number of prior regimens was 3 (range 1-9); 27% had high risk FISH. All pts had prior lenalidomide and proteasome inhibitors (bortezomib 94%, 76% carfilzomib) and were refractory to their last line of therapy. Prior therapies also included: auto SCT (45%), pomalidomide (36%), daratumumab (21%), and isatuximab (3%). 31 pts were assessable for response (2 patients did not complete cycle 1 due to rapid disease progression or stroke and were not evaluable). The median length of follow up was 3.3 months (range 0.5-18.2): 23 pts continue on study; 7 pts discontinued for progressive disease and 3 pts discontinued for adverse events (AEs) (sepsis, pneumonia, or stroke). Best ORR was 52% (PR = 11, VGPR = 4, CR = 1); ORR for pts with prior anti-CD38 antibody, 43%; carfilzomib, 43%; pomalidomide, 40%. Median PFS was 9.7 months (95% CI 7.5-Inf). Grade 3-4 hematologic AEs included anemia (7%), neutropenia (34%), and thrombocytopenia (17%). Common non-hematologic AEs all grades included fatigue (38%), upper respiratory infection (38%), constipation (38%), hyperglycemia (38%), and neuropathy (38%, Gr 1-2 only), with 2 possibly related deaths (sepsis, pneumonia). Conclusions: Elo-PVD shows encouraging responses in patients with refractory MM. Treatment was well-tolerated with manageable toxicity and attention to infectious AEs. Clinical trial information: NCT02718833." @default.
• W2890779740 created "2018-09-27" @default.
• W2890779740 creator A5007237464 @default.
• W2890779740 creator A5016437820 @default.
• W2890779740 creator A5022030260 @default.
• W2890779740 creator A5027328800 @default.
• W2890779740 creator A5028356065 @default.
• W2890779740 creator A5032177345 @default.
• W2890779740 creator A5042842421 @default.
• W2890779740 creator A5043322435 @default.
• W2890779740 creator A5043526996 @default.
• W2890779740 creator A5046070614 @default.
• W2890779740 creator A5049711954 @default.
• W2890779740 creator A5050075424 @default.
• W2890779740 creator A5051006606 @default.
• W2890779740 creator A5052163068 @default.
• W2890779740 creator A5055089118 @default.
• W2890779740 creator A5055832458 @default.
• W2890779740 creator A5058065952 @default.
• W2890779740 creator A5065395869 @default.
• W2890779740 creator A5084831561 @default.
• W2890779740 creator A5087265191 @default.
• W2890779740 date "2018-05-20" @default.
• W2890779740 modified "2023-10-17" @default.
• W2890779740 title "A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma." @default.
• W2890779740 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.8012" @default.
• W2890779740 hasPublicationYear "2018" @default.
• W2890779740 type Work @default.
• W2890779740 sameAs 2890779740 @default.
• W2890779740 citedByCount "5" @default.
• W2890779740 countsByYear W28907797402018 @default.
• W2890779740 countsByYear W28907797402021 @default.
• W2890779740 countsByYear W28907797402023 @default.
• W2890779740 crossrefType "journal-article" @default.
• W2890779740 hasAuthorship W2890779740A5007237464 @default.
• W2890779740 hasAuthorship W2890779740A5016437820 @default.
• W2890779740 hasAuthorship W2890779740A5022030260 @default.
• W2890779740 hasAuthorship W2890779740A5027328800 @default.
• W2890779740 hasAuthorship W2890779740A5028356065 @default.
• W2890779740 hasAuthorship W2890779740A5032177345 @default.
• W2890779740 hasAuthorship W2890779740A5042842421 @default.
• W2890779740 hasAuthorship W2890779740A5043322435 @default.
• W2890779740 hasAuthorship W2890779740A5043526996 @default.
• W2890779740 hasAuthorship W2890779740A5046070614 @default.
• W2890779740 hasAuthorship W2890779740A5049711954 @default.
• W2890779740 hasAuthorship W2890779740A5050075424 @default.
• W2890779740 hasAuthorship W2890779740A5051006606 @default.
• W2890779740 hasAuthorship W2890779740A5052163068 @default.
• W2890779740 hasAuthorship W2890779740A5055089118 @default.
• W2890779740 hasAuthorship W2890779740A5055832458 @default.
• W2890779740 hasAuthorship W2890779740A5058065952 @default.
• W2890779740 hasAuthorship W2890779740A5065395869 @default.
• W2890779740 hasAuthorship W2890779740A5084831561 @default.
• W2890779740 hasAuthorship W2890779740A5087265191 @default.
• W2890779740 hasConcept C126322002 @default.
• W2890779740 hasConcept C141071460 @default.
• W2890779740 hasConcept C143998085 @default.
• W2890779740 hasConcept C197934379 @default.
• W2890779740 hasConcept C2776063141 @default.
• W2890779740 hasConcept C2776364478 @default.
• W2890779740 hasConcept C2776694085 @default.
• W2890779740 hasConcept C2777063308 @default.
• W2890779740 hasConcept C2777478702 @default.
• W2890779740 hasConcept C2778524551 @default.
• W2890779740 hasConcept C2778822529 @default.
• W2890779740 hasConcept C2780108899 @default.
• W2890779740 hasConcept C2780401358 @default.
• W2890779740 hasConcept C2781119759 @default.
• W2890779740 hasConcept C71924100 @default.
• W2890779740 hasConcept C90924648 @default.
• W2890779740 hasConceptScore W2890779740C126322002 @default.
• W2890779740 hasConceptScore W2890779740C141071460 @default.
• W2890779740 hasConceptScore W2890779740C143998085 @default.
• W2890779740 hasConceptScore W2890779740C197934379 @default.
• W2890779740 hasConceptScore W2890779740C2776063141 @default.
• W2890779740 hasConceptScore W2890779740C2776364478 @default.
• W2890779740 hasConceptScore W2890779740C2776694085 @default.
• W2890779740 hasConceptScore W2890779740C2777063308 @default.
• W2890779740 hasConceptScore W2890779740C2777478702 @default.
• W2890779740 hasConceptScore W2890779740C2778524551 @default.
• W2890779740 hasConceptScore W2890779740C2778822529 @default.
• W2890779740 hasConceptScore W2890779740C2780108899 @default.
• W2890779740 hasConceptScore W2890779740C2780401358 @default.
• W2890779740 hasConceptScore W2890779740C2781119759 @default.
• W2890779740 hasConceptScore W2890779740C71924100 @default.
• W2890779740 hasConceptScore W2890779740C90924648 @default.
• W2890779740 hasIssue "15_suppl" @default.
• W2890779740 hasLocation W28907797401 @default.
• W2890779740 hasOpenAccess W2890779740 @default.
• W2890779740 hasPrimaryLocation W28907797401 @default.
• W2890779740 hasRelatedWork W2034770517 @default.
• W2890779740 hasRelatedWork W2061838129 @default.
• W2890779740 hasRelatedWork W2580225813 @default.
• W2890779740 hasRelatedWork W2903721846 @default.
• W2890779740 hasRelatedWork W3085958492 @default.
• W2890779740 hasRelatedWork W4205941672 @default.
• W2890779740 hasRelatedWork W4289835730 @default.
• W2890779740 hasRelatedWork W4319754513 @default.

• next